Form 4: United Therapeutics CEO Rothblatt Executes Stock Option Sales Under 10b5-1 Plan
SEC Form 4
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on August 7th and 8th, 2024.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The transactions involved the exercise of stock options at a price of $129.49 and subsequent sales of common stock on August 7th and 8th, 2024.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- The plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
- The sales occurred at varying prices, with weighted average prices reported for each day's transactions.
- Following the reported transactions, Rothblatt directly owns 43,469 derivative securities.
- Rothblatt also has indirect ownership through various family trusts.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions under a pre-existing plan, indicating a neutral sentiment.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring December 31, 2024, or August 31, 2024.
Industry Context
Executive stock sales are common and often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan provides a legal framework for these transactions.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings and avoid insider trading concerns.
- Comparable companies such as Gilead Sciences, Amgen, and Biogen also see regular Form 4 filings related to executive stock transactions.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Date exercisable for stock options |
| 08/04/2023 | Date of establishment of 10b5-1 trading plan |
| 08/07/2024 | Date of first transaction (exercise and sale) |
| 08/08/2024 | Date of second transaction (exercise and sale) |
| 08/09/2024 | Date of filing |
| 08/31/2024 | End date of 10b5-1 trading plan (if options not exhausted) |
| 12/31/2024 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.